Alternative PSA screening strategies could reduce harm

February 5, 2013
Alternative PSA screening strategies could reduce harm
Compared with standard screening, alternative prostate-specific antigen screening strategies could maintain good prostate cancer detection rates while reducing overdiagnoses and unnecessary biopsies, according to research published in the Feb. 5 issue of the Annals of Internal Medicine.

(HealthDay)—Compared with standard screening, alternative prostate-specific antigen (PSA) screening strategies could maintain good prostate cancer detection rates while reducing overdiagnoses and unnecessary biopsies, according to research published in the Feb. 5 issue of the Annals of Internal Medicine.

Roman Gulati, of the Fred Hutchinson Cancer Research Center in Seattle, and colleagues assessed the of alternative strategies using a microsimulation model of prostate cancer incidence in a contemporary cohort of U.S. men. Thirty-five screening strategies were compared that varied by start and stop age, interval, and threshold for biopsy referral.

The researchers found that the risk for prostate was 2.86 percent without screening. The risk was reduced to 2.15 percent (with a 3.3 percent risk of overdiagnosis) with a reference strategy that screens men aged 50 to 74 years annually with a PSA threshold of 4 µg/L for biopsy referral. Use of a higher PSA threshold among older men was associated with a 2.23 percent risk of prostate cancer death and a decrease in the risk of overdiagnosis to 2.3 percent. A biennial screening strategy with longer screening intervals for men with low was associated with a 2.27 percent risk of prostate cancer death and a 2.4 percent risk of overdiagnosis. In addition, this strategy correlated with a 59 percent reduction in total tests and a 50 percent reduction in false-positive results.

"If we recognize that realistic screening strategies must achieve an acceptable balance of benefits and harms as opposed to unconditionally maximizing benefits, we can improve on the effectiveness of existing PSA-based screening for prostate cancer," the authors write.

Explore further: A new screening method for prostate cancer

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

A new screening method for prostate cancer

February 2, 2012

A new study by NYU Langone Medical Center and Northwestern University Feinberg School of Medicine shows novel PSA velocity (PSAV) risk count testing may provide a more effective way for physicians to screen men for clinically ...

Benefits of prostate-specific antigen testing remain unclear

July 20, 2012

(HealthDay) -- It remains unclear whether the benefits of prostate-specific antigen (PSA) testing outweigh the harms, but evidence suggests that men with a longer life expectancy may benefit from testing, according to a provisional ...

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.